ABSTRACT
Abstract Purpose: To analyze the preoperative serum matrix metalloproteinase-9 (MMP-9) levels and prognosis of patients with hilar cholangiocarcinoma (HC) undergoing radical resection. Methods: Preoperative serum MMP-9 levels in patients with HC undergoing radical resection were detected by enzyme-linked immunosorbent assay (ELISA). The ROC curve assay was used to analyze the preoperative serum MMP-9 level to determine the most valuable cut-off point. The relationship between MMP-9 and clinicopathological features of HC patients was analyzed. Kaplan-Meier method was used to analyze the prognostic factors, and COX regression model was used to analyze the independent risk factors affecting prognosis. Results: Preoperative serum MMP-9 levels were significantly elevated in the death patients compared with the survival patients. The most valuable cut-off point for preoperative serum MMP-9 for prognosis was 201.93 ng/mL. Preoperative serum MMP-9 was associated with Bismuth-Corlette classification) and lymph node metastasis. Kaplan-Meier analysis showed that MMP-9, Bismuth-Corlette classification, Lymph node metastasis, Portal vein invasion, Hepatic artery invasion, Liver invasion, Incised margin, and Preoperative biliary drainage were related to prognosis. Cox regression model confirmed that hepatic artery invasion, liver invasion, incised margin, and MMP-9 have the potential to independence predicate prognosis in HC patients. Conclusion: Preoperative serum MMP-9 has high predictive value for prognosis and is an independent influencing factor for the prognosis of patients with hilar cholangiocarcinoma.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Bile Duct Neoplasms/surgery , Bile Duct Neoplasms/blood , Klatskin Tumor/surgery , Klatskin Tumor/blood , Matrix Metalloproteinase 9/blood , Postoperative Period , Prognosis , Reference Values , Time Factors , Bile Duct Neoplasms/mortality , Bile Duct Neoplasms/pathology , Enzyme-Linked Immunosorbent Assay , Multivariate Analysis , Risk Factors , ROC Curve , Klatskin Tumor/mortality , Klatskin Tumor/pathology , Kaplan-Meier Estimate , Preoperative Period , Neoplasm InvasivenessABSTRACT
Abstract: Introduction and aims. Cholangiocarcinomas are a heterogeneous group of tumors that can be classified into three clinically distinct types of cancers, intrahepatic, perihilar and distal cholangiocarcinoma. The inconsistent use of nomenclature for these cancers has obscured a true knowledge of the epidemiology, natural history and response to therapy of these cancers. Our aims were to define demographic characteristics, management and outcomes of these three distinct cancer types. Materials and methods. A retrospective study of patients enrolled in an institutional cancer registry from 1992 to 2010. Median survival was compared between different treatment modalities over three time periods for the three types of cholangiocarcinoma at different stages of the disease using Kaplan Meyer analysis. Results. 242 patients were identified. All cases were reviewed and classified into intrahepatic (90 patients), distal (48 patients) or perihilar (104 patients) cholangiocarcinomas. These cancers differed in median age of onset, gender distribution, median survival and stage. 13.8% of patients presented with stage I, 5.8% with stage II, 9.6% with stage III, 28% with stage IV, with 41.8% having unknown stage. The overall median survival was 15.8 months, and was 23, 25, 14, and 4.5 months for stages I, II, III, and IV respectively. Surgery improved survival in both early and advanced stages. Multimodality therapies further improved outcomes, particularly for perihilar cholangiocarcinoma. Conclusion. Perihilar, distal and intrahepatic cholangiocarcinoma vary in their presentation, natural history and therapeutic approach to management. A consistently applied classification is essential for meaningful interpretation of studies of these cancers.
Subject(s)
Humans , Middle Aged , Aged , Bile Duct Neoplasms/therapy , Biliary Tract Surgical Procedures , Cholangiocarcinoma/therapy , Antineoplastic Agents/therapeutic use , Time Factors , Bile Duct Neoplasms/classification , Bile Duct Neoplasms/mortality , Bile Duct Neoplasms/pathology , Biliary Tract Surgical Procedures/adverse effects , Biliary Tract Surgical Procedures/mortality , Registries , Florida , Retrospective Studies , Treatment Outcome , Chemotherapy, Adjuvant , Klatskin Tumor/classification , Klatskin Tumor/mortality , Klatskin Tumor/pathology , Klatskin Tumor/therapy , Cholangiocarcinoma/classification , Cholangiocarcinoma/mortality , Cholangiocarcinoma/pathology , Radiotherapy, Adjuvant , Kaplan-Meier Estimate , Neoplasm Staging , Antineoplastic Agents/adverse effectsABSTRACT
As recent advances in chemotherapy and surgical treatment have improved outcomes in patients with biliary cancers, the search for an optimal strategy for relief of their obstructive jaundice has become even more important. Without satisfactory relief of biliary obstruction, many patients would be ineligible for treatment. We review all prospective randomized trials and recent retrospective non-randomized studies for evidence that would support such a strategy. For distal malignant biliary obstruction, an optimal strategy would be insertion of metallic stents either endoscopically or percutaneously. Evidence shows that a metallic stent inserted percutaneously has better outcomes than plastic stents inserted endoscopically. For malignant hilar obstruction, percutaneous biliary drainage with or without metallic stents is preferred.